Salas MQ, Charry P, Pedraza A, Martinez-Cibrian N, Solano MT, Domenech A, et al. PTCY and Tacrolimus for GVHD prevention for older adults undergoing HLA-matched sibling and unrelated donor AlloHCT. Transpl Cell Ther. 2022;28:489 e1–e9.
Nunes NS, Kanakry CG. Mechanisms of Graft-versus-Host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668.
Article CAS PubMed PubMed Central Google Scholar
Clifton K, Barnett C, Martinez A, Karuturi M, Saleem S, Litton J. Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. Breast J. 2018;24:691–2.
Bruining DM, van Roon EN, de Graaf H, Hoogendoorn M. Cyclophosphamide-induced symptomatic hyponatraemia. Neth J Med. 2011;69:192–5.
Lee YC, Park JS, Lee CH, Bae SC, Kim IS, Kang CM, et al. Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transpl. 2010;25:1520–4.
Teles KA, Medeiros-Souza P, Lima FAC, Araujo BG, Lima RAC. Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Rev Bras Reumatol Engl Ed. 2017;57:596–604.
Chen J, Jin Y, Li C, Li Z. Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: a case report. Medicine. 2020;99:e22498.
Article PubMed PubMed Central Google Scholar
Shepshelovich D, Schechter A, Calvarysky B, Diker-Cohen T, Rozen-Zvi B, Gafter-Gvili A. Medication-induced SIADH: distribution and characterization according to medication class. Br J Clin Pharm. 2017;83:1801–7.
Park SJ, Kim JH, Shin JI. Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transpl. 2010;25:3453.
Kim S, Jo CH, Kim GH. The role of vasopressin V2 receptor in drug-induced hyponatremia. Front Physiol. 2021;12:797039.
Article PubMed PubMed Central Google Scholar
Koo TY, Bae SC, Park JS, Lee CH, Park MH, Kang CM, et al. Water intoxication following low-dose intravenous cyclophosphamide. Electrolyte Blood Press. 2007;5:50–4.
留言 (0)